ReviewClinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association2014
Direct-acting antiviral agents and the path to interferon independence.
Review in Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- A human vaccine strategy based on chimpanzee adenoviral and MVA vectors that primes, boosts, and sustains functional HCV-specific T cell memory.Science translational medicine · 2014Trial
- Metalloprotoporphyrin Inhibition of HCV NS3-4A Protease: Structure-Activity Relationships.Drug design, development and therapy · 2020Article
- Laboratory Diagnosis and Monitoring of Viral Hepatitis.Gastroenterology clinics of North America · 2019Review
- Article
- Risk of hepatocellular carcinoma after sustained virological response in Veterans with hepatitis C virus infection.Hepatology (Baltimore, Md.) · 2016Article
- The natural history of recent hepatitis C virus infection among blood donors and injection drug users in the country of Georgia.Virology journal · 2016Article
- New prospects for the treatment and prevention of hepatitis C in children.Current opinion in pediatrics · 2016Review
- Targeting the Channel Activity of Viroporins.Advances in protein chemistry and structural biology · 2016Review
- Hepatitis C genotype 4: The past, present, and future.World journal of hepatology · 2015Review
- A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.Journal of hepatology · 2015Article
- Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program.Journal of general internal medicine · 2015Article
- Hepatitis B and C in pregnancy: a review and recommendations for care.Journal of perinatology : official journal of the California Perinatal Association · 2014Review
- Clinical outcomes of hepatitis B virus coinfection in a United States cohort of hepatitis C virus-infected patients.Hepatology (Baltimore, Md.) · 2014Article
- Pathogenesis and prevention of hepatitis C virus-induced hepatocellular carcinoma.Journal of hepatology · 2014Review
- Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: molecular mechanisms and clinical significance.Emerging microbes & infections · 2014Review
- Hepatitis C-related liver cirrhosis - strategies for the prevention of hepatic decompensation, hepatocarcinogenesis, and mortality.World journal of gastroenterology · 2014Review
- Finally sofosbuvir: an oral anti-HCV drug with wide performance capability.Pharmacogenomics and personalized medicine · 2014Review
- Interferon-free regimens and direct-acting antiviral agents.Gastroenterology & hepatology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Chronic infection with hepatitis C virus (HCV) is a major global health problem; there are approximately 120 to 130 million chronic infections worldwide. Since the discovery of HCV 24 years ago, there has been a relentless effort to develop successful antiviral therapies. Studies of interferon-α-based therapies have helped define treatment parameters, and these treatment strategies have cured a substantial percentage of patients. However, interferon-α must be injected; there are problems with tolerability, adherence, and incomplete response in a large percentage of patients. New drug candidates designed to target the virus or the host have recently been introduced at an unprecedented pace. In phase I-III studies, these agents have exceeded expectations and achieved rates of response previously not thought possible. We are, therefore, entering a new era of therapy for HCV infection and interferon independence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.